The future: surgical advances in MEN1 therapeutic approaches and management strategies.
Multiple endocrine neoplasia type 1 (MEN1) is a hereditary autosomal dominant disorder associated with numerous neuroendocrine tumors (NETs). Recent advances in the management of MEN1 have led to a decrease in mortality due to excess hormones; however, they have also led to an increase in mortality from malignancy, particularly NETs. The main challenges are to localize these tumors, to select those that need therapy because of the risk of aggressive behavior and to select the appropriate therapy associated with minimal morbidity. This must be applied to a hereditary disease with a high risk of recurrence. The overall aim of management in MEN1 is to ensure that the patient remains disease- and symptom-free for as long as possible and maintains a good quality of life. Herein, we review the changes that occurred in the last 20 years in the surgical management of MEN1-associated functional and non-functional pancreatico-duodenal NETs and thymic and bronchial NETs.
['Sadowski|S M|SM|', 'Cadiot|G|G|', 'Dansin|E|E|', 'Goudet|P|P|', 'Triponez|F|F|']
D006801:Humans D018761:Multiple Endocrine Neoplasia Type 1 D018358:Neuroendocrine Tumors
multiple endocrine neoplasia type 1 (MEN1) lung NET neuro-endocrine tumors (NET) pancreatico-gastro-intestinal NET thymic NET